FINDEX Inc.
TTSE:3649872.00
JPY
-6.00
(-0.68%)
ISIN
JP3801450002
Return %
Stock
S&P 500
1Y
2.11
14.20
3Y
-1.36
81.12
5Y
-9.73
68.34
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.Company Description
- CEO
- Teruo Aibara
- Full Time Employees
- 325
- Sector
- Technology services
- Industry
- Packaged software
- Address
- Tokyo Sankei Bldg Tokyo Japan 100-0004
- IPO Date
- Mar 23, 2011
- Website
- findex.co.jp
- Similar Companies
- Business
- FINDEX Inc. is a Japan-based R&D technology company specializing in the development and sale of medical data management systems, document management systems, and health tech solutions. Its core product offerings include medical data management software such as Claio; medical consultation efficiency tools like Medical Avenue; cloud-based services under the PiCls brand including PiCls Referral and PiCls Booking Assistant; electronic tracing report AAde-Report; gaze analyzing perimeter GAP-screener for eye-tracking analysis related to mild cognitive impairment; and document management systems including DocuMaker Office. The company operates primarily in the healthcare, public sector, and health tech industries, targeting medical institutions, government agencies, and research organizations across Japan with expanding efforts in global ophthalmology markets. Founded in 1985 and headquartered in Tokyo, FINDEX also focuses on integrating AI and cloud computing into its product ecosystem, including generative AI products like CocktailAI and second digital certificate services for electronic prescriptions. Recent strategic developments in the last 1-2 years include launching the PiCls cloud-based service brand in September 2023, strengthening digital networking solutions in healthcare, expanding multi-channel marketing, and entering several large-scale projects serving over 5,000 users per facility. The company continues its growth strategy under a Medium-Term Business Plan "Vision for 2025," targeting record sales and profit margins supported by enhanced product features and new distributor partnerships. FINDEX transitioned EMC Healthcare Co., Ltd. from a consolidated subsidiary to an equity-method affiliate in July 2022 and has made significant operational and organizational changes, including moving to the Tokyo head office and advancing cloud-based services with integrated AI functionalities. It also pursues research in medical technology areas such as drug discovery support and mild cognitive impairment detection using eye-tracking technologies. The company recorded substantial revenue and profit growth in fiscal 2024 driven by increased outsourcing related to data migration and strategic investments in human resources. FINDEX also engages in public sector system development and health tech business segmentation, offering support services like CocktailAI and maintaining a focus on medical DX (digital transformation) solutions aligned with Japan's Next Generation Medical Infrastructure Act. Its market presence is reinforced through partnerships and ongoing expansion of its core medical and public sector product lines, with an emphasis on cloud, SaaS, and cross-selling strategies to increase customer adoption and product functionality. The company remains publicly listed on the Tokyo Stock Exchange Prime Market under ticker 3649.T.